Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Fineline Cube Aug 4, 2026
Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Fineline Cube Aug 4, 2026
Company Drug

Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China

Fineline Cube Jan 7, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...

Company Drug

Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 7, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...

Policy / Regulatory

NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jan 7, 2025

The National Medical Products Administration (NMPA) has released the 88th batch of reference drugs for...

Company Drug

Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment

Fineline Cube Jan 7, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has indicated...

Company Drug

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager

Fineline Cube Jan 7, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Drug

Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials

Fineline Cube Jan 7, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...

Company Deals

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making

Fineline Cube Jan 7, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially submitted an initial public offering (IPO)...

Company Deals

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization

Fineline Cube Jan 7, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...

Policy / Regulatory

CDE Announces 90th Batch of Reference Preparations for GQCE

Fineline Cube Jan 7, 2025

China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...

Company Deals Drug

Solasia Pharma Licenses Episil to GeneScience for Greater China Region

Fineline Cube Jan 7, 2025

Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...

Company Deals

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines

Fineline Cube Jan 7, 2025

Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...

Company Drug

GSK’s Nucala Receives New Indication Approval in China for CRSwNP

Fineline Cube Jan 6, 2025

UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...

Policy / Regulatory

China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access

Fineline Cube Jan 6, 2025

The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...

Company Deals

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau

Fineline Cube Jan 6, 2025

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...

Company Deals Medical Device

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development

Fineline Cube Jan 6, 2025

China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...

Company Deals

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Fineline Cube Jan 6, 2025

China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...

Company Drug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...

Company Deals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Fineline Cube Jan 6, 2025

China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...

Company Medical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Fineline Cube Jan 6, 2025

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...

Posts pagination

1 … 270 271 272 … 702

Recent updates

  • Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer
  • Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
  • Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke
  • CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer
  • Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Company Drug

Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke

Company Drug

CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.